- In December 2023, Max Healthcare successfully introduced CAR-T cell therapy in the Delhi-NCR area, marking a significant advancement in cancer treatment options. This innovative therapy, developed in partnership with ImmunoACT, is specifically designed to combat lymphomas and leukemias, offering new hope for patients battling these challenging conditions
- In December 2022, CARsgen Therapeutics Co., Ltd. partnered with the Shanghai Cancer Institute to develop new technology that significantly enhances the antitumor effectiveness of T cells. Their research team discovered that CAR T cells engineered to overexpress Runx3 exhibited sustained antitumor activity and improved tumor control compared to traditional chimeric antigen receptor T-cell therapies
- In November 2022, Caribou Biosciences, Inc. announced that its allogeneic anti-CD19 CAR-T cell therapy, CB-010, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for relapsed or refractory large B cell lymphoma (LBCL), as well as fast track designation for relapsed or refractory B cell non-Hodgkin lymphoma
- In June 2022, The University of Ottawa showcased promising results from the Canadian-Led Immunotherapies in Cancer-01 (CLIC-01) clinical trial, which focused on one of the first Canadian-developed CAR-T cell therapies for cancer. This therapy features a unique manufacturing process that may lead to more affordable and equitable treatment options
- In November 2021, The California Institute for Regenerative Medicine's governing board approved a grant of USD 4.1 million to support the advancement of innovative chimeric antigen receptor T-cell therapy being developed by scientists at the University of California San Diego School of Medicine, aiding their efforts to transition this promising cancer treatment from the laboratory to clinical practice
